Mulpleo (Lusutrombopag)

Lusutrombopag acts on the thrombopoietin receptor pathway to manage low platelet counts.

• Thrombocytopenia in chronic liver disease undergoing invasive procedures: Increases platelet counts to allow safe surgery or diagnostic interventions.
• Pre‑operative thrombocytopenia in patients with cirrhosis: Facilitates adequate platelet levels before elective operations.
• Platelet deficiency in liver transplant candidates: Supports hemostasis to reduce peri‑operative bleeding risk.

• Lusutrombopag selectively binds to the thrombopoietin (c‑Mpl) receptor on megakaryocyte precursors, mimicking the natural ligand. This activation triggers intracellular signaling that promotes megakaryocyte proliferation and maturation, leading to increased platelet production and elevated circulating platelet counts in patients with impaired thrombopoiesis.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea: occasional, often transient.
• Fatigue: reported during early treatment.
• Diarrhoea: usually mild and self‑limiting.

Serious or Rare Side Effects

• Thrombotic events: including portal vein thrombosis.
• Hepatic dysfunction: elevated liver enzymes.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should assess individual risk factors and monitor relevant parameters.

• Bleeding risk assessment: evaluate baseline platelet count and bleeding history.
• History of thrombosis: avoid in patients with recent thrombotic episodes.
• Liver function monitoring: check hepatic enzymes periodically.
• Concurrent anticoagulants: use with caution and adjust dosing as needed.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Lusutrombopag may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid)

• Other thrombopoietin receptor agonists: additive effect on platelet production.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase drug exposure and risk of adverse events.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Antiplatelet agents (e.g., aspirin, clopidogrel): may alter bleeding risk.
• Anticoagulants (e.g., warfarin, DOACs): monitor coagulation parameters.
• NSAIDs: increased gastrointestinal bleeding potential.